Dr. Kavita Patel joins ‘Fast Money’ to talk Eli Lilly’s GLP-1 entrant cutting diabetes risk, the weight-loss drugs sector as a whole, and more.
05:59
Tue, Aug 20 20246:18 PM EDT
Trending
- A broken merger opens up an opportunity for investors to scoop up a value stock
- why Bernstein’s Rasgon thinks investors must have Nvidia exposure
- Common investing mistake to avoid in the Trump years
- UFC’s Dana White joins Meta’s board weeks before Trump takes office
- What we learned in NFL Week 18: Lions show grit, Broncos take care of business
- How the sports media world is undergoing a seismic shift
- Why Fidelity’s top quant market strategist is bullish on financials for 2025
- Ulta Beauty names new CEO Kecia Steelman to replace Dave Kimbell
Eli Lilly’s Zepbound may be best-in-breed for weight loss drugs, says Dr. Kavita Patel
